Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer

Figure 2

Prognostic signature model structuring and validating. (a, b) The risk scores and distribution of patients from TCGA (a) and ICGC (b). (c, d) PCA plots of the training (c) and testing cohorts (d). (e, f) Results of t-SNE analysis in the training (e) and testing cohorts (f). (g, h) Survival status distribution of patients from TCGA (g) and ICGC (h). (i, j) Kaplan–Meier curves for the training (i) and testing groups (j). (k, l) the ROC curves in the training (k) and the testing sets (l).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)